Alpha‐lipoic acid decreases hepatic lipogenesis through adenosine monophosphate‐activated protein kinase (AMPK)‐dependent and AMPK‐independent pathways

• Published in: Hepatology (Baltimore, Md.) Vol. 48; no. 5; pp. 1477 - 1486
• Main Authors: Park, Keun‐Gyu, Min, Ae‐Kyung, Koh, Eun Hee, Kim, Hyoun Sik, Kim, Mi‐Ok, Park, Hye‐Sun, Kim, Yong‐Deuk, Yoon, Tae‐Seung, Jang, Byoung Kuk, Hwang, Jae Seok, Kim, Jae Bum, Choi, Hueng‐Sik, Park, Joong‐Yeol, Lee, In‐Kyu, Lee, Ki‐Up
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.11.2008
• Subjects: AMP-Activated Protein Kinases; Carcinoma, Hepatocellular; Cell Line, Tumor; Enzyme Activation; Fatty Liver - enzymology; Fatty Liver - genetics; Fatty Liver - pathology; Fatty Liver - physiopathology; Humans; Insulin Resistance; Kinetics; Lipids - biosynthesis; Liver - drug effects; Liver - pathology; Liver - physiology; Liver Neoplasms; Multienzyme Complexes - genetics; Multienzyme Complexes - metabolism; Obesity - genetics; Obesity - physiopathology; Protein-Serine-Threonine Kinases - genetics; Protein-Serine-Threonine Kinases - metabolism; RNA, Messenger - genetics; Thioctic Acid - pharmacology; Triglycerides - metabolism
• ISSN: 0270-9139; 1527-3350; 1527-3350
• DOI: 10.1002/hep.22496

Fatty liver is common in obese subjects with insulin resistance. Hepatic expression of sterol regulatory element binding protein‐1c (SREBP‐1c), which plays a major role in hepatic steatosis, is regulated by multiple factors, including insulin, adenosine monophosphate–activated protein kinase (AMPK), liver X receptors (LXRs), and specificity protein 1. Alpha‐lipoic acid (ALA), a naturally occurring antioxidant, has been shown to decrease lipid accumulation in skeletal muscle by activating AMPK. Here we show that ALA decreases hepatic steatosis and SREBP‐1c expression in rats on a high fat diet or given an LXR agonist. ALA increased AMPK phosphorylation in the liver and in cultured liver cells, and dominant‐negative AMPK partially prevented ALA‐induced suppression of insulin‐stimulated SREBP‐1c expression. ALA also inhibited DNA‐binding activity and transcriptional activity of both specificity protein 1 and LXR. Conclusion: These results show that ALA prevents fatty liver disease through multiple mechanisms, and suggest that ALA can be used to prevent the development and progression of nonalcoholic fatty liver disease in patients with insulin resistance. (HEPATOLOGY 2008.)